EPISODE · Apr 14, 2026 · 11 MIN
Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year
from BiotechTV - News · host BiotechTV
After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience and how Korro has new momentum with a galNAc delivered approach targeting urea cycle disorders, hepatic encephalophy, and new alpha-1 program. The company recently closed a $85 private placement.
What this episode covers
After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience and how Korro has new momentum with a galNAc delivered approach targeting urea cycle disorders, hepatic encephalophy, and new alpha-1 program. The company recently closed a $85 private placement.
NOW PLAYING
Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.